Repligen Corporation - Common Stock — Filings & Documents (NASDAQ:RGEN) — Page 10 | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

1995

Quarterly report, Q2 FY1995

REPLIGEN CORP quarterly report, Q2 FY1995

Annual report, Q1 FY1995

REPLIGEN CORP annual report, Q1 FY1995

1
2
3
4
5
6
7
8
9
10

News

Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?

ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know

Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

5 Biotech Stocks Worth Adding to Your Portfolio Now

J&J's Imaavy Gets FDA Approval as the First Treatment for wAIHA

GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer

Acadia Gets European Commission Nod for Daybu in Rett Syndrome

HALO Stock Rises 36% in a Month: Here's What You Should Know

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

MRK/MRNA's Personalized Cancer Therapy Delivers First Phase III Win

RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos